Skip to main content

Articles

Page 1 of 72

  1. Our previous study first showed that ATR-binding long noncoding RNA (lncRNA) is necessary for ATR function and promotes cancer resistance. However, the specific lncRNAs instrumental in ATR activation remain la...

    Authors: Yuanyuan Chen, Hui Shen, Tingting Liu, Kun Cao, Zhijie Wan, Zhipeng Du, Hang Wang, Yue Yu, Shengzhe Ma, Edward Lu, Wei Zhang, Jianming Cai, Fu Gao and Yanyong Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:256
  2. Chronic stress promotes most hallmarks of cancer through impacting the malignant tissues, their microenvironment, immunity, lymphatic flow, etc. Existing studies mainly focused on the roles of stress-induced a...

    Authors: Jun Pan, Leyi Zhang, Xiaomei Wang, Lili Li, Chenghui Yang, Zhen Wang, Ke Su, Xiaoxiao Hu, Yi Zhang, Guohong Ren, Jiahuan Jiang, Peng Li and Jian Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:255
  3. The upregulation of antioxidant mechanisms is a common occurrence in cancer cells, as they strive to maintain balanced redox state and prevent oxidative damage. This includes the upregulation of the cystine/gl...

    Authors: Roberto Ruiu, Chiara Cossu, Antonella Iacoviello, Laura Conti, Elisabetta Bolli, Luca Ponzone, Jolanda Magri, Alekya Rumandla, Enzo Calautti and Federica Cavallo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:254
  4. Chimeric antigen receptor (CAR)-T immunotherapy fails to treat solid tumors due in part to immunosuppressive microenvironment. Excess lactate produced by tumor glycolysis increases CAR-T immunosuppression. The...

    Authors: Ting Sun, Bin Liu, Yanyan Li, Jie Wu, Yufei Cao, Shuangyu Yang, Huiling Tan, Lize Cai, Shiqi Zhang, Xinyue Qi, Dingjia Yu and Wei Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:253
  5. NONO-TFE3 rearranged renal cell carcinoma (NONO-TFE3 rRCC) is one of a subtype of TFE3 rRCCs with high malignancy and poor prognosis. Compared with clear cell RCC, NONO-TFE3 rRCC shows a preference for mitochondr...

    Authors: Yi Chen, Yanwen Lu, Lei Yang, Wenliang Ma, Yuhan Dong, Shuoming Zhou, Ning Liu, Weidong Gan and Dongmei Li
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:252
  6. Clinical drawback in checkpoint inhibitors immunotherapy (ICI) of metastatic melanoma (MM) is monitoring clinical benefit. Soluble forms of PD1(sPD1) and PD-L1(sPD-L1) and extracellular vesicles (EVs) expressi...

    Authors: Simona Serratì, Roberta Di Fonte, Letizia Porcelli, Simona De Summa, Ivana De Risi, Livia Fucci, Eustachio Ruggieri, Tommaso Maria Marvulli, Sabino Strippoli, Rossella Fasano, Tania Rafaschieri, Gabriella Guida, Michele Guida and Amalia Azzariti
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:251
  7. Ewing sarcoma (ES) is an aggressive childhood bone and soft tissue cancer. KIAA1429 is one type of N6-methyladenosine (m6A) writer that plays a tumor-progressive role in various cancers, but the role of KIAA1429 ...

    Authors: Kezhe Tan, Wenjie Lu, Feng Chen, Hao Shi, Yingxuan Ma, Zhou Chen, Wei Wu, Zhibao Lv and Jialin Mo
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:250
  8. Hypoxia is one of most typical features in the tumor microenvironment of solid tumor and an inducer of endoplasmic reticulum (ER) stress, and HIF-1α functions as a key transcription factor regulator to promote...

    Authors: Hongyu Yuan, Zitong Zhao, Jing Xu, Ruiping Zhang, Liying Ma, Jing Han, Weihong Zhao, Mingzhou Guo and Yongmei Song
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:249
  9. The most common site of metastasis in colorectal cancer (CRC) is the liver and liver metastases occur in more than 50% of patients during diagnosis or treatment. The occurrence of metastasis depends on a serie...

    Authors: Guangshun Sun, Siqi Zhao, Zhongguo Fan, Yuliang Wang, Hanyuan Liu, Hengsong Cao, Guoqiang Sun, Tian Huang, Hongzhou Cai, Hong Pan, Dawei Rong, Yun Gao and Weiwei Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:248
  10. Tumor biopsy is often not available or difficult to obtain in patients with solid tumors. Investigation of the peripheral immune system allows for in-depth and dynamic profiling of patient immune response prio...

    Authors: Nicole J. Toney, Jeffrey Schlom and Renee N. Donahue
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:247
  11. Gastric cancer (GC) is one of the most prevalent malignant tumors of the digestive system. As a hallmark of cancer, energy-related metabolic reprogramming is manipulated by multiple factors, including long non...

    Authors: Cong Zhang, Huixia Wang, Qingwei Liu, Suli Dai, Guo Tian, Xintong Wei, Xiaoya Li, Lianmei Zhao and Baoen Shan
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:246
  12. Macrophages are highly plastic in different tissues and can differentiate into functional subpopulations under different stimuli. Tumor-associated macrophages (TAMs) are one of the most important innate immune...

    Authors: Wentao Zeng, Fei Li, Shikai Jin, Ping-Chih Ho, Pu-Ste Liu and Xin Xie
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:245
  13. Glioblastoma (GBM) is the most malignant among gliomas with an inevitable lethal outcome. The elucidation of the physiology and regulation of this tumor is mandatory to unravel novel target and effective thera...

    Authors: Alberto Visioli, Nadia Trivieri, Gandino Mencarelli, Fabrizio Giani, Massimiliano Copetti, Orazio Palumbo, Riccardo Pracella, Maria Grazia Cariglia, Chiara Barile, Luigi Mischitelli, Amata Amy Soriano, Pietro Palumbo, Federico Legnani, Francesco DiMeco, Leonardo Gorgoglione, Graziano Pesole…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:244
  14. Authors: Lifa Huang, Xu Li, Hui Ye, Yajun Liu, Xiaolong Liang, Chao Yang, Lin Hua, Zhaoxian Yan and Xin Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:243

    The original article was published in Journal of Experimental & Clinical Cancer Research 2020 39:63

  15. Glioma exhibit heterogeneous susceptibility for targeted ferroptosis. How circRNAs alterations in glioma promote iron metabolism and ferroptosis defense remains unclarified.

    Authors: Chengbin Wang, Minjie Zhang, Yingliang Liu, Daming Cui, Liang Gao and Yang Jiang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:242
  16. Authors: Yulin Peng, Yan Wang, Ning Tang, Dongdong Sun, Yulong Lan, Zhenlong Yu, Xinyu Zhao, Lei Feng, Baojing Zhang, Lingling Jin, Fabiao Yu, Xiaochi Ma and Chuanzhu Lv
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:241

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:248

  17. Authors: Yi Zhang, Qinshan Li, Honglin Liu, Hongting Tang, Hanlin Yang, Daoqiu Wu, Yuying Huang, Licheng Li, Lihong Liu and Mengxing Li
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:240

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:219

  18. Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with a poor prognosis. The underlying functions and mechanisms of circular RNA and SUMOylation in the development of ICC remain poorly understood.

    Authors: Junhao Zheng, Yali Wang, Liye Tao, Jingwei Cai, Zefeng Shen, Yang Liu, Haoyu Pan, Shihao Li, Yeling Ruan, Tianyi Chen, Zhengtao Ye, Kainan Lin, Yin Sun, Junjie Xu and Xiao Liang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:239
  19. Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain la...

    Authors: Chunhua She, Chao Wu, Weihua Guo, Yongjie Xie, Shouyi Li, Weishuai Liu, Chao Xu, Hui Li, Pei Cao, Yanfang Yang, Xiuchao Wang, Antao Chang, Yukuan Feng and Jihui Hao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:238
  20. Chemotherapeutic agents are used to control tumor proliferation. However, their influence in the pre-metastatic niche of target organs has not been well studied. Oxaliplatin (OXA) is a drug applied in standard...

    Authors: Yuanyuan Ma, Chang Guo, Xijun Wang, Xundong Wei and Jie Ma
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:237
  21. Fusobacterium nucleatum (Fn) acts as a procarcinogenic bacterium in colorectal carcinoma (CRC) by regulating the inflammatory tumor microenvironment (TME). Neutrophil extracellular traps (NETs), which can be gene...

    Authors: Xuehua Kong, Yu Zhang, Linwei Xiang, Yan You, Yaqian Duan, Yuqing Zhao, Shue Li, Rui Wu, Jiangbo Zhang, Lan Zhou and Liang Duan
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:236
  22. Malignant ascites commonly occurs in advanced or recurrent stages of epithelial ovarian cancer during peritoneal carcinomatosis and is correlated with poor prognosis. Due to its complex composition of cellular...

    Authors: Antonio Hrvat, Mathias Schmidt, Bernd Wagner, Denise Zwanziger, Rainer Kimmig, Lothar Volbracht, Sven Brandau and Nina Mallmann-Gottschalk
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:235
  23. Neoadjuvant radiotherapy has been used as the standard treatment of colorectal cancer (CRC). However, radiotherapy resistance often results in treatment failure. To identify radioresistant genes will provide n...

    Authors: Tingting Liu, Hang Wang, Yuanyuan Chen, Zhijie Wan, Zhipeng Du, Hui Shen, Yue Yu, Shengzhe Ma, Ying Xu, Zhuqing Li, Nanxi Yu, Fangxiao Zhang, Kun Cao, Jianming Cai, Wei Zhang, Fu Gao…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:234
  24. Sec23 homolog A (SEC23A), a core component of coat protein complex II (COPII), has been reported to be involved in several cancers. However, the role of SEC23A in gastric cancer remains unclear.

    Authors: Quan Cheng, Kanghui Liu, Jian Xiao, Kuan Shen, Yuanhang Wang, Xinyi Zhou, Jiawei Wang, Zekuan Xu and Li Yang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:232
  25. Acute lymphoblastic leukemia (ALL) is the most common pediatric hematological malignancy, with ETV6::RUNX1 being the most prevalent translocation whose exact pathogenesis remains unclear. IGF2BP1 (Insulin-like Gr...

    Authors: Gunjan Sharma, Tiffany M. Tran, Ishu Bansal, Mohammad Sabique Beg, Ruchi Bhardwaj, Jaspal Bassi, Yuande Tan, Amit Kumar Jaiswal, Christine Tso, Ayushi Jain, Jay Singh, Parthaprasad Chattopadhyay, Archna Singh, Anita Chopra, Sameer Bakhshi, David Casero…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:231
  26. Most of the endometrial cancer (EC) patients are diagnosis in early stage with a good prognosis while the patients with locally advanced recurrent or metastatic result in a poor prognosis. Adjuvant therapy cou...

    Authors: Xi Chen, Xin Liu, Qian-hui Li, Bing-feng Lu, Bu-min Xie, Yu-meng Ji and Yang Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:230
  27. As a subclass of endogenous stable noncoding RNAs, circular RNAs are beginning to be appreciated for their potential as tumor therapeutics. However, the functions and mechanisms by which circRNAs exert protect...

    Authors: Deze Zhao, Yeping Dong, Minghao Duan, Dan He, Qun Xie, Wei Peng, Weifang Cui, Junjie Jiang, Yuanda Cheng, Heng Zhang, Faqing Tang, Chunfang Zhang, Yang Gao and Chaojun Duan
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:229
  28. Accumulating evidence has demonstrated that aberrant expression of deubiquitinating enzymes is associated with the initiation and progression of Triple-negative breast cancer (TNBC). The publicly available TCG...

    Authors: Zhitao Han, Qi Jia, Jing Zhang, Miaomiao Chen, Lining Wang, Kai Tong, Weiwei He, Yajie Zhang, Weina Zhu, Ju Qin, Tao Wang, Tielong Liu, Yong Ma, Yuanming Chen, Siluo Zha and Chunlei Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:228
  29. Breast cancer (BC) is the leading cause of morbidity and the second leading cause of death among female malignant tumors. Although available drugs have been approved for the corresponding breast cancer subtype...

    Authors: Hong Yang, Xiangjin Zhen, Yihui Yang, Yizhi Zhang, Sen Zhang, Yue Hao, Guanhua Du, Hongquan Wang, Bailin Zhang, Wan Li and Jinhua Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:227
  30. Breast cancer is one of the frequent tumors that seriously endanger the physical and mental well-being in women. F-box and WD repeat domain-containing 7 (FBXW7) is a neoplastic repressor. Serving as a substrat...

    Authors: Siyu Chen, Ping Leng, Jinlin Guo and Hao Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:226
  31. Tumors have evolved in various mechanisms to evade the immune system, hindering the antitumor immune response and facilitating tumor progression. Immunotherapy has become a potential treatment strategy specifi...

    Authors: Hongli Gao, Jianqiao Yin, Ce Ji, Xiaopeng Yu, Jinqi Xue, Xin Guan, Shuang Zhang, Xun Liu and Fei Xing
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:225
  32. FAT4 (FAT Atypical Cadherin 4) is a member of the cadherin-associated protein family, which has been shown to function as a tumor suppressor by inhibiting proliferation and metastasis. The Wnt/β-catenin pathwa...

    Authors: Dongying Wang, Shuying Wu, Jiaxing He, Luguo Sun, Hongming Zhu, Yuxuan Zhang, Shanshan Liu, Xuefeng Duan, Yanhong Wang and Tianmin Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:222
  33. Acute myeloid leukemia (AML) patients bearing the ITD mutation in the tyrosine kinase receptor FLT3 (FLT3-ITD) present a poor prognosis and a high risk of relapse. FLT3-ITD is retained in the endoplasmic retic...

    Authors: Francesca Liccardo, Martyna Śniegocka, Claudia Tito, Alessia Iaiza, Tiziana Ottone, Mariadomenica Divona, Serena Travaglini, Maurizio Mattei, Rosella Cicconi, Selenia Miglietta, Giuseppe Familiari, Stefania Annarita Nottola, Vincenzo Petrozza, Luca Tamagnone, Maria Teresa Voso, Silvia Masciarelli…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:223
  34. Lung cancer remains the leading cause of cancer-related deaths globally, and the survival rate remains low despite advances in diagnosis and treatment. The progression of lung cancer is a multifaceted and dyna...

    Authors: Naushad Ahmad Khan, Mohammad Asim, Kabir H. Biswas, Amani N Alansari, Harman Saman, Mohammad Zahid Sarwar, Kudaibergen Osmonaliev and Shahab Uddin
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:221
  35. Authors: E. C. de Heer, C. E. Zois, E. Bridges, B. van der Vegt, H. Sheldon, W. A. Veldman, M. C. Zwager, T. van der Sluis, S. Haider, T. Morita, O. Baba, C. P. Schröder, S. de Jong, A. L. Harris and M. Jalving
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:220

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:143

  36. The Makorin ring finger protein 1 (MKRN1) gene, also called RNF61, is located on the long arm of chromosome 7 and is a member of the RING finger protein family. The E3 ubiquitin ligase MKRN1 is closely linked to ...

    Authors: Yi Zhang, Qin-shan Li, Hong-lin Liu, Hong-ting Tang, Han-lin Yang, Dao-qiu Wu, Yu-ying Huang, Li-cheng Li, Li-hong Liu and Meng-xing Li
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:219

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2023 42:240

  37. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, characterized by restricted cellular subsets with asymmetrically enriched leukemia initiating cell (LIC) activity. Nonethe...

    Authors: Emanuele Murgo, Elisabetta De Santis, Francesca Sansico, Valentina Melocchi, Tommaso Colangelo, Costanzo Padovano, Mattia Colucci, Annalucia Carbone, Beatrice Totti, Alireza Basti, Lisa Gottschlich, Angela Relogio, Nazzareno Capitanio, Fabrizio Bianchi, Gianluigi Mazzoccoli and Vincenzo Giambra
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:218
  38. Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; howeve...

    Authors: Kai Lin, Endi Zhou, Ting Shi, Siqing Zhang, Jinfan Zhang, Ziruo Zheng, Yuetian Pan, Wentao Gao and Yabin Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:217
  39. In addition to specifically inducing tumor cell apoptosis, recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has also been reported to influence the cancer immune microenvironme...

    Authors: Xupu Wang, Lizheng Wang, Wenmo Liu, Xinyao Liu, Xinyuan Jia, Xinyao Feng, Fangshen Li, Rui Zhu, Jiahao Yu, Haihong Zhang, Hui Wu, Jiaxin Wu, Chu Wang, Bin Yu and Xianghui Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:216
  40. N7-methylguanosine (m7G) modification is, a more common epigenetic modification in addition to m6A modification, mainly found in mRNA capsids, mRNA interiors, transfer RNA (tRNA), pri-miRNA, and ribosomal RNA ...

    Authors: Mingpeng Zhang, Duo Kan, Boya Zhang, Xueqiao Chen, Chun Wang, Songmao Chen, Wenlong Gao, Zhao Yang, Yang Li, Yutong Chen, Shimiao Zhu, Simeng Wen, Yuanjie Niu and Zhiqun Shang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:215
  41. Medulloblastoma (MB) is the most common cerebellar malignancy during childhood. Among MB, MYC-amplified Group 3 tumors display the worst prognosis. MYC is an oncogenic transcription factor currently thought to...

    Authors: Consuelo Pitolli, Alberto Marini, Marika Guerra, Marco Pieraccioli, Veronica Marabitti, Fernando Palluzzi, Luciano Giacò, Gianpiero Tamburrini, Francesco Cecconi, Francesca Nazio, Claudio Sette and Vittoria Pagliarini
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:214
  42. There is increasing evidence indicating the significant role of DDX5 (also called p68), acting as a master regulator and a potential biomarker and target, in tumorigenesis, proliferation, metastasis and treatm...

    Authors: Fengzhi Li, Xiang Ling, Sayan Chakraborty, Christos Fountzilas, Jianmin Wang, Anmbreen Jamroze, Xiaozhuo Liu, Pawel Kalinski and Dean G. Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:213
  43. Authors: Matteo Centonze, Giusy Di Conza, Michael Lahn, Isabel Fabregat, Francesco Dituri, Isabella Gigante, Grazia Serino, Rosanna Scialpi, Livianna Carrieri, Roberto Negro, Elena Pizzuto and Gianluigi Giannelli
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:211

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:197

  44. Despite tremendous progress in deciphering breast cancer at the genomic level, the pronounced intra- and intertumoral heterogeneity remains a major obstacle to the advancement of novel and more effective treat...

    Authors: Nicole Anderle, Felix Schäfer-Ruoff, Annette Staebler, Nicolas Kersten, André Koch, Cansu Önder, Anna-Lena Keller, Simone Liebscher, Andreas Hartkopf, Markus Hahn, Markus Templin, Sara Y. Brucker, Katja Schenke-Layland and Christian Schmees
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:210
  45. Prostate cancer threatens the health of men over sixty years old, and its incidence ranks first among all urinary tumors among men. Enzalutamide remains the first-line drug for castration-resistant prostate ca...

    Authors: Qingzhuo Dong, Hui Qiu, Chiyuan Piao, Zhengxiu Li and Xiaolu Cui
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:209
  46. Authors: Bing Liu, Hongye Ma, Qianqian Liu, Yang Xiao, Shimeng Pan, Huimin Zhou and Li Jia
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:208

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:200

  47. The advances in cancer research achieved in the last 50 years have been remarkable and have provided a deeper knowledge of this disease in many of its conceptual and biochemical aspects. From viewing a tumor a...

    Authors: Alexandra Sala, James M. Cameron, Paul M. Brennan, Emma J. Crosbie, Tom Curran, Ewan Gray, Pierre Martin-Hirsch, David S. Palmer, Ihtesham U. Rehman, Nicholas J. W. Rattray and Matthew J. Baker
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:207

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2022 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    97 days submission to accept (Median)

    2022 Usage 
    2,694,347 downloads
    4,666 Altmetric mentions